组织学亚型定制的新辅助化疗对比标准化疗治疗高危软组织肉瘤(ISG-STS 1001):一项国际、开放标签、随机对照、3期、多中心试验
该国际随机3期试验纳入287例高危肢体或躯干壁软组织肉瘤患者,比较组织学亚型定制新辅助化疗与标准化疗。第三次无效性分析时中位随访12.3个月,标准化疗组46个月无病生存率62%,定制组38%,风险比为2.00,试验因无效提前终止。
要点
- 在高危软组织肉瘤中,组织学亚型定制新辅助化疗未显示优于标准化疗。
- 标准化疗组46个月无病生存率为62%,定制组为38%,分层log-rank p=0.004。
- 定制组疾病复发或死亡风险约为标准化疗组的2倍(HR 2.00,95%CI 1.22-3.26)。
核心结论
- 在高危软组织肉瘤患者中,未显示组织学亚型定制新辅助化疗方案优于标准化疗方案。
- 标准化疗方案所见的获益提示该获益可能是新辅助化疗本身在高危软组织肉瘤患者中的附加价值。
研究设计与样本
- 研究为国际、开放标签、随机对照、3期、多中心试验,在意大利、西班牙、法国和波兰的32家医院入组患者。
- 纳入年龄18岁及以上、肢体或躯干壁局部高危(高恶性度、直径5 cm或以上、按 Investing 筋膜深部位置)软组织肉瘤且属于五种组织学亚型之一的患者。
- 患者按1:1随机分配接受三周期标准全剂量化疗或组织学亚型定制化疗,随机按术前放疗和国家分层。
- 主要终点为无病生存期,主要和安全性分析在意向治疗人群中进行,每年进行意向治疗基础上的无效性分析。
- 2011年5月19日至2016年5月13日共随机分配287例患者(标准化疗组145例,定制组142例),除标准化疗组1例外均纳入疗效分析。
主要发现
- 第三次无效性分析时中位随访12.3个月(IQR 2.75-28.20),标准化疗组46个月预计无病生存率为62%(95%CI 48-77),定制组为38%(22-55)(分层log-rank p=0.004;HR 2.00,95%CI 1.22-3.26;p=0.006)。
- 标准化疗组(n=125)最常见的3级或以上不良事件为中性粒细胞减少(107例[86%])、贫血(24例[19%])和血小板减少(21例[17%]);定制组(n=114)最常见的3级或以上不良事件为中性粒细胞减少(30例[26%])。
- 两组均未报告治疗相关死亡。
- 与独立数据监查委员会一致,研究在第三次无效性分析后停止入组。
关键数值与推荐
- 标准化疗方案:表柔比星60 mg/m2/天(第1、2天短时输注)联合异环磷酰胺3 g/m2/天(第1、2、3天),每21天重复,共三周期。
- 高恶性度黏液样脂肪肉瘤定制方案:曲贝替定1.3 mg/m2,24小时持续输注,每21天重复。
- 平滑肌肉瘤定制方案:吉西他滨1800 mg/m2第1天静脉输注180分钟联合达卡巴嗪500 mg/m2第1天静脉输注20分钟,每14天重复。
- 滑膜肉瘤定制方案:高剂量异环磷酰胺14 g/m2,经外部输注泵14天给药,每28天重复。
- 恶性外周神经鞘瘤定制方案:依托泊苷150 mg/m2/天(第1、2、3天)联合异环磷酰胺3 g/m2/天(第1、2、3天),每21天重复;未分化多形性肉瘤定制方案:吉西他滨900 mg/m2第1、8天静脉输注90分钟联合多西他赛75 mg/m2第8天静脉输注1小时,每21天重复。
临床怎么用
- 在高危软组织肉瘤患者中,组织学亚型定制新辅助化疗方案未显示优于标准化疗方案。
- 标准化疗方案所见的获益提示该获益可能是新辅助化疗本身在高危软组织肉瘤患者中的附加价值。
局限性
- 原文报告在第三次无效性分析时因无效而提前终止入组。
- 中位随访时间为12.3个月(IQR 2.75-28.20),随访时间较短。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Previous trials from our group suggested an overall survival benefit with five cycles of adjuvant full-dose epirubicin plus ifosfamide in localised high-risk soft-tissue sarcoma of the extremities or trunk wall, and no difference in overall survival benefit between three cycles versus five cycles of the same neoadjuvant regimen. We aimed to show the superiority of the neoadjuvant administration of histotype-tailored regimen to standard chemotherapy. METHODS: For this international, open-label, randomised, controlled, phase 3, multicentre trial, patients were enrolled from 32 hospitals in Italy, Spain, France, and Poland. Eligible patients were aged 18 years or older with localised, high-risk (high malignancy grade, 5 cm or longer in diameter, and deeply located according to the investing fascia), soft-tissue sarcoma of the extremities or trunk wall and belonging to one of five histological subtypes: high-grade myxoid liposarcoma, leiomyosarcoma, synovial sarcoma, malignant peripheral nerve sheath tumour, and undifferentiated pleomorphic sarcoma. Patients were randomly assigned (1:1) to receive three cycles of full-dose standard chemotherapy (epirubicin 60 mg/m2 per day [short infusion, days 1 and 2] plus ifosfamide 3 g/m2 per day [days 1, 2, and 3], repeated every 21 days) or histotype-tailored chemotherapy: for high-grade myxoid liposarcoma, trabectedin 1·3 mg/m2 via 24-h continuous infusion, repeated every 21 days; for leiomyosarcoma, gemcitabine 1800 mg/m2 on day 1 intravenously over 180 min plus dacarbazine 500 mg/m2 on day 1 intravenously over 20 min, repeated every 14 days; for synovial sarcoma, high-dose ifosfamide 14 g/m2, given over 14 days via an external infusion pump, every 28 days; for malignant peripheral nerve sheath tumour, intravenous etoposide 150 mg/m2 per day (days 1, 2, and 3) plus intravenous ifosfamide 3 g/m2 per day (days 1, 2, and 3), repeated every 21 days; and for undifferentiated pleomorphic sarcoma, gemcitabine 900 mg/m2 on days 1 and 8 intravenously over 90 min plus docetaxel 75 mg/m2 on day 8 intravenously over 1 h, repeated every 21 days. Randomisation was stratified by administration of preoperative radiotherapy and by country of enrolment. Computer-generated random lists were prepared by use of permuted balanced blocks of size 4 and 6 in random sequence. An internet-based randomisation system ensured concealment of the treatment assignment until the patient had been registered into the system. No masking of treatment assignments was done. The primary endpoint was disease-free survival. The primary and safety analyses were planned in the intention-to-treat population. We did yearly futility analyses on an intention-to-treat basis. The study was registered with ClinicalTrials.gov, number NCT01710176, and with the European Union Drug Regulating Authorities Clinical Trials, number EUDRACT 2010-023484-17, and is closed to patient entry. FINDINGS: Between May 19, 2011, and May 13, 2016, 287 patients were randomly assigned to a group (145 to standard chemotherapy and 142 to histotype-tailored chemotherapy), all of whom, except one patient assigned to standard chemotherapy, were included in the efficacy analysis (97 [34%] with undifferentiated pleomorphic sarcoma; 64 [22%] with high-grade myxoid liposarcoma; 70 [24%] with synovial sarcoma; 27 [9%] with malignant peripheral nerve sheath tumour; and 28 [10%] with leiomyosarcoma). At the third futility analysis, with a median follow-up of 12·3 months (IQR 2·75-28·20), the projected disease-free survival at 46 months was 62% (95% CI 48-77) in the standard chemotherapy group and 38% (22-55) in the histotype-tailored chemotherapy group (stratified log-rank p=0·004; hazard ratio 2·00, 95% CI 1·22-3·26; p=0·006). The most common grade 3 or higher adverse events in the standard chemotherapy group (n=125) were neutropenia (107 [86%]), anaemia (24 [19%]), and thrombocytopenia (21 [17%]); the most common grade 3 or higher adverse event in the histotype-tailored chemotherapy group (n=114) was neutropenia (30 [26%]). No treatment-related deaths were reported in both groups. In agreement with the Independent Data Monitoring Committee, the study was closed to patient entry after the third futility analysis. INTERPRETATION: In a population of patients with high-risk soft-tissue sarcoma, we did not show any benefit of a neoadjuvant histotype-tailored chemotherapy regimen over the standard chemotherapy regimen. The benefit seen with the standard chemotherapy regimen suggests that this benefit might be the added value of neoadjuvant chemotherapy itself in patients with high-risk soft-tissue sarcoma. FUNDING: European Union grant (Eurosarc FP7 278472).
引用
- Gronchi A, Ferrari S, Quagliuolo V, et al. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. Lancet Oncol. 2017. PMID: 28499583. doi:10.1016/S1470-2045(17)30334-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。